Physician profile
Richard A Caner
NPI 1104888502
$10,527.76
in general payments reported to CMS, 2019-2025
56 companies · $683 in 2025
The $683 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,130 · 2020: $2,172 · 2021: $2,063 · 2022: $1,173 · 2023: $449 · 2024: $858 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,206.03 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Collegium Pharmaceutical, INC. | $1,053.25 | 2019-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $908.59 | 2019-2025 | Relistor |
| Medtronic USA, INC. | $643.65 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $474.89 | 2019-2022 | |
| Pfizer INC. | $445.56 | 2019-2025 | |
| Allergan, INC. | $404.24 | 2019-2022 | |
| Tersera Therapeutics LLC | $374.26 | 2019-2025 | Prialt |
| Abbott Laboratories | $360.71 | 2020-2022 | |
| Medtronic, INC. | $341.27 | 2021-2022 | |
| Sentynl Therapeutics, INC. | $324.19 | 2019-2020 | |
| Lilly USA, LLC | $297.78 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $280.17 | 2019-2023 | Austedo Xr |
| Horizon Therapeutics Plc | $272.01 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $265.92 | 2019-2021 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Caner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.